DOMINGO P, FRANCIA E, TORRES O, MONTIEL JA, PEREZ A, ORDONEZ J, SAMBEAT MA, VAZQUEZ G; Interscience Conference on Antimicrobial Agents and Chemotherapy.
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2000 Sep 17-20; 40: 314.
Hosp. de la Santa Creu i Sant Pau, Barcelona, Spain
Objective: To compare body composition, serum lipid profile lipid, insulin secretion, and endocrine measurements in HIV-1-infected patients whose antiretroviral regime differed only in a nucleoside reverse transcriptase inhibitor (NRTI). Patients and Methods: Ninety-eight HIV-infected patients on long-term highly active antiretroviral therapy including stavudine (n=95) or zidovudine (n=23). Fat wasting was assessed by physical examination. Regional fat distribution was estimated using caliper measurements of skinfold thickness at four sites. Central adiposity was assessed by measurement of waist-hip ratio. Fasting glucose, insulin, triglyceride, cholesterol, testosterone, follicle stimulating hormone, luteinizing hormone levels, CD4 cell count, and HIV viral load were determined.RESULTS: Both groups were well balanced with respect to age, sex duration of HIV infection, risks factors for acquiring HIV infection, prior AIDS defining conditions, duration of HAART, daily caloric intake, CD4 cell counts, HIV-1 RNA and percent of undetectacble plasma viral load. The mean time of exposure to NRTIs prior to HAART was not significantly different (46.9+/-30.7 vs. 45.0+/-32.1 months, p=.81). The lean body mass and fat parameters of body composition were similar among the groups. There were no statistically significant differences between the skinfold thickness measured at four different sites, nor there were between arm and leg or metabolic parameters.Visceral adiposity estimated through the waist-hip ratio was not statistically different in both groups. Conclusion: There were not differences with respect to anthropometric or metabolic parameters between patients heavily pre-treated with NRTIs who received a stavudine-based or a zidovudine-based HAART.KEYWORDS: Lipodystrophy; Stavudine; Zidovudine
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- Antiretroviral Therapy, Highly Active
- Body Composition
- CD4 Lymphocyte Count
- Cadherins
- Fats
- HIV
- HIV Infections
- HIV Protease Inhibitors
- HIV Seropositivity
- HIV-1
- Humans
- Lipodystrophy
- Reverse Transcriptase Inhibitors
- Stavudine
- Viral Load
- Zidovudine
- immunology
Other ID:
UI: 102247940
From Meeting Abstracts